| abstract |
The present invention presents the EP4 receptor antagonist compound (or pharmaceutically acceptable salt thereof) of formula I as defined herein, alone or in antibody therapy, radiation therapy, anti-metabolites. Concerning the use of EP4 receptor antagonist compounds for treating cancer or inflammatory disease by administration to the required subject in combination with chemotherapy. Formula I [Selection diagram] None |